WT1 TCR transduced T cells

WT1 TCR transduced T cells is an autologous, gene-modified adoptive T-cell therapy originally developed by researchers at University College London (UCL) and Imperial College London, and later developed by Cell Medica (via Catapult Therapy TCR). The therapy involves engineering a patient's own T cells to express a specific T-cell receptor (TCR) targeting the Wilms' tumor 1 (WT1) protein. WT1 is a transcription factor that is highly overexpressed in various hematological malignancies and solid tumors, while showing minimal expression in normal adult tissues, making it a suitable target for immunotherapy. The product was evaluated in a Phase I/II clinical trial for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had failed hypomethylating agent therapy, though the trial was terminated early. Cell Medica also explored using its Dominant TCR platform to improve the efficacy of these cells in solid tumors like mesothelioma and ovarian cancer.

Other names

WT1-specific TCR-transduced T-cell therapyWT-1-specific TCR-transduced T-cell therapyWT 1-specific TCR-transduced T-cell therapyautologous WT1-specific TCR-engineered T cellsWT1-TCR gene-modified T-cellsWT-1-TCR gene-modified T-cellsWT 1-TCR gene-modified T-cells